HRP20121048T1 - Reverzna genetika korištenjem ne-endogenih pol i promotora - Google Patents
Reverzna genetika korištenjem ne-endogenih pol i promotora Download PDFInfo
- Publication number
- HRP20121048T1 HRP20121048T1 HRP20121048AT HRP20121048T HRP20121048T1 HR P20121048 T1 HRP20121048 T1 HR P20121048T1 HR P20121048A T HRP20121048A T HR P20121048AT HR P20121048 T HRP20121048 T HR P20121048T HR P20121048 T1 HRP20121048 T1 HR P20121048T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- pol
- promoter
- expression
- cell
- Prior art date
Links
- 241000700605 Viruses Species 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 claims 7
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 claims 7
- 108020000999 Viral RNA Proteins 0.000 claims 6
- 241000282465 Canis Species 0.000 claims 3
- 241000288906 Primates Species 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 230000002457 bidirectional effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16041—Use of virus, viral particle or viral elements as a vector
- C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
- C12N2760/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Mushroom Cultivation (AREA)
Claims (15)
1. Postupak za dobivanje rekombinantnog virusa, koji da sadrži korak uzgoja pseće stanice domaćina koja sadrži barem jedan ekspresijski konstrukt koji kodira virusnu RNK molekulu, naznačen time da je ekspresija virusne RNK molekule iz konstrukta kontrolirana pomoću pol I promotora od primata pod uvjetima da je eksprimirana virusna RNK molekula kako bi se proizveo virus.
2. Postupak za dobivanje virusa, naznačen time da sadrži korake: (i) proizvodnje rekombinantnog virusa postupkom prema zahtjevu 1; (ii) infekcije kultiviranog domaćina sa virusom dobivenim u koraku (i); (iii) uzgoja domaćina iz koraka (ii) da se proizvede dodatni virus; i (iv) pročišćavanja virusa dobivenog u koraku (iii).
3. Postupak za dobivanje cjepiva, naznačen time da sadrži korake (a) pripreme virusa postupkom prema zahtjevu 2 i (b) pripreme cjepiva od virusa.
4. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da pol I promotor je ljudski pol I promotor.
5. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da stanica je MDCK stanica.
6. Postupak prema zahtjevu 5 naznačen time da MDCK stanica je stanična linija MDCK 33016 (DSM ACC2219).
7. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da stanica sadrži barem jedan dvosmjerni ekspresijski konstrukt.
8. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da ekspresijski konstrukt je ekspresijski vektor ili linearni ekspresijski konstrukt.
9. Postupak prema bilo kojem od zahtjeva 4 do 8, naznačen time da ljudski pol I promotor sadrži sekvencu SEQ ID NO: 1 ili SEQ ID NO: 2.
10. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da virus je segmentirani virus.
11. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da virus je ne- segmentirani virus.
12. Postupak prema bilo kojem prethodnom zahtjevu naznačen time da virus je negativni RNK virus.
13. Postupak prema zahtjevu 12 naznačen time da virus je virus influence.
14. Pseća stanica domaćin koja proizvodi virus, koja sadrži barem jedan ekspresijski konstrukt koji kodira virusnu RNK molekulu, naznačena time da je ekspresija virusne RNK molekule iz konstrukta kontrolirana pomoću pol I promotora od primata.
15. Pseća stanica koja proizvodi virus, naznačena time da ima barem jedan endogeni pol I promotor koji kontrolira(ju) ekspresiju endogene rRNK i barem jedan ne-endogeni pol I promotor primata koji kontrolira(ju) ekspresiju virusne RNK ili njezin komplement.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21691909P | 2009-05-21 | 2009-05-21 | |
| PCT/IB2010/001332 WO2010133964A1 (en) | 2009-05-21 | 2010-05-21 | Reverse genetics using non-endogenous pol i promoters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121048T1 true HRP20121048T1 (hr) | 2013-02-28 |
Family
ID=42338045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121048AT HRP20121048T1 (hr) | 2009-05-21 | 2012-12-18 | Reverzna genetika korištenjem ne-endogenih pol i promotora |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9072702B2 (hr) |
| EP (2) | EP2401384B1 (hr) |
| JP (2) | JP5836266B2 (hr) |
| KR (1) | KR101800245B1 (hr) |
| CN (1) | CN102597246B (hr) |
| AU (1) | AU2010250832B2 (hr) |
| BR (1) | BRPI1011171A2 (hr) |
| CA (1) | CA2762802A1 (hr) |
| DK (1) | DK2401384T3 (hr) |
| EA (1) | EA021009B1 (hr) |
| ES (1) | ES2394797T3 (hr) |
| HK (1) | HK1165827A1 (hr) |
| HR (1) | HRP20121048T1 (hr) |
| NZ (1) | NZ596432A (hr) |
| PL (1) | PL2401384T3 (hr) |
| PT (1) | PT2401384E (hr) |
| SI (1) | SI2401384T1 (hr) |
| SM (1) | SMT201300034B (hr) |
| WO (1) | WO2010133964A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| WO2010133964A1 (en) * | 2009-05-21 | 2010-11-25 | Novartis Ag | Reverse genetics using non-endogenous pol i promoters |
| KR101323582B1 (ko) * | 2011-03-17 | 2013-10-30 | 충북대학교 산학협력단 | Ｖｅｒｏ 세포 유래의 ｐｏｌⅠ 프로모터 및 이를 포함하는 재조합 벡터 |
| CN105120893B (zh) | 2012-12-03 | 2018-11-13 | 诺华股份有限公司 | 流感病毒重配 |
| EP2968512A2 (en) | 2013-03-13 | 2016-01-20 | Novartis AG | Influenza b virus reassortment |
| WO2014195920A2 (en) | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
| WO2016148195A1 (ja) * | 2015-03-17 | 2016-09-22 | 一般財団法人阪大微生物病研究会 | インフルエンザウイルス作出用細胞 |
| EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| US20230000971A1 (en) | 2019-11-18 | 2023-01-05 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
| BR102020010208A2 (pt) | 2020-05-21 | 2022-04-12 | Fundação Oswaldo Cruz | Construção de ácido nucleico, virus influenza recombinante, método para preparar um virus influenza recombinante, composição, e, uso. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| BR0014281A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Vacina contra vìrus de gripe intranasal |
| CA2401117C (en) | 2000-03-03 | 2010-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| EP2269639B1 (en) | 2001-02-23 | 2018-11-28 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
| JP2004536785A (ja) | 2001-02-23 | 2004-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| CA2421086A1 (fr) * | 2003-02-28 | 2004-08-28 | Institut Pasteur | Promoteur de l'arn polymerase i de poulet et son utilisation |
| SI1742659T1 (sl) | 2004-04-05 | 2013-07-31 | Zoetis P Llc | Mikrofluidizirane emulzije olja v vodi in sestavki cepiv |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| DK2368975T3 (en) | 2004-12-23 | 2015-01-05 | Medimmune Llc | Non-tumorigenic MDCK cell line for the propagation of viruses |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US20060286591A1 (en) | 2005-06-21 | 2006-12-21 | Medimmune Vaccines, Inc. | Methods and compositions for expressing negative-sense viral RNA in canine cells |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| WO2007052163A2 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| JP5491173B2 (ja) | 2006-04-19 | 2014-05-14 | メディミューン，エルエルシー | イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物 |
| MX2009003325A (es) | 2006-10-12 | 2009-04-09 | Glaxosmithkline Biolog Sa | Vacuna que comprende un adyuvante de emulsion de aceite en agua. |
| EA200900784A1 (ru) | 2006-12-06 | 2009-12-30 | Новартис Аг | Вакцины, включающие антиген из четырех штаммов вируса гриппа |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| WO2010133964A1 (en) * | 2009-05-21 | 2010-11-25 | Novartis Ag | Reverse genetics using non-endogenous pol i promoters |
-
2010
- 2010-05-21 WO PCT/IB2010/001332 patent/WO2010133964A1/en active Application Filing
- 2010-05-21 CA CA2762802A patent/CA2762802A1/en not_active Abandoned
- 2010-05-21 PT PT107245854T patent/PT2401384E/pt unknown
- 2010-05-21 JP JP2012511364A patent/JP5836266B2/ja active Active
- 2010-05-21 AU AU2010250832A patent/AU2010250832B2/en active Active
- 2010-05-21 US US13/320,902 patent/US9072702B2/en active Active
- 2010-05-21 ES ES10724585T patent/ES2394797T3/es active Active
- 2010-05-21 NZ NZ596432A patent/NZ596432A/xx unknown
- 2010-05-21 SI SI201030099T patent/SI2401384T1/sl unknown
- 2010-05-21 BR BRPI1011171-9A patent/BRPI1011171A2/pt not_active Application Discontinuation
- 2010-05-21 EA EA201171449A patent/EA021009B1/ru unknown
- 2010-05-21 EP EP10724585A patent/EP2401384B1/en active Active
- 2010-05-21 KR KR1020117030081A patent/KR101800245B1/ko active IP Right Grant
- 2010-05-21 PL PL10724585T patent/PL2401384T3/pl unknown
- 2010-05-21 CN CN201080027545.1A patent/CN102597246B/zh active Active
- 2010-05-21 DK DK10724585.4T patent/DK2401384T3/da active
- 2010-05-21 EP EP12186937A patent/EP2573184A1/en not_active Withdrawn
-
2012
- 2012-07-03 HK HK12106430.1A patent/HK1165827A1/xx unknown
- 2012-12-18 HR HRP20121048AT patent/HRP20121048T1/hr unknown
-
2013
- 2013-03-27 SM SM201300034T patent/SMT201300034B/xx unknown
-
2015
- 2015-05-07 US US14/706,866 patent/US20160024525A1/en not_active Abandoned
- 2015-08-17 JP JP2015160273A patent/JP2015204843A/ja active Pending
-
2019
- 2019-01-30 US US16/261,955 patent/US20190284575A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA021009B1 (ru) | 2015-03-31 |
| KR20120028328A (ko) | 2012-03-22 |
| HK1165827A1 (en) | 2012-10-12 |
| AU2010250832B2 (en) | 2013-10-03 |
| AU2010250832A1 (en) | 2011-12-08 |
| CN102597246B (zh) | 2014-02-26 |
| EP2401384B1 (en) | 2012-10-03 |
| DK2401384T3 (da) | 2013-01-14 |
| US20190284575A1 (en) | 2019-09-19 |
| WO2010133964A1 (en) | 2010-11-25 |
| JP5836266B2 (ja) | 2015-12-24 |
| EP2401384A1 (en) | 2012-01-04 |
| KR101800245B1 (ko) | 2017-11-22 |
| JP2015204843A (ja) | 2015-11-19 |
| EP2573184A1 (en) | 2013-03-27 |
| US20120189656A1 (en) | 2012-07-26 |
| SMT201300034B (it) | 2013-05-06 |
| NZ596432A (en) | 2013-05-31 |
| JP2012527228A (ja) | 2012-11-08 |
| CA2762802A1 (en) | 2010-11-25 |
| US20160024525A1 (en) | 2016-01-28 |
| EA201171449A1 (ru) | 2012-05-30 |
| PT2401384E (pt) | 2012-12-19 |
| PL2401384T3 (pl) | 2013-03-29 |
| US9072702B2 (en) | 2015-07-07 |
| BRPI1011171A2 (pt) | 2015-08-25 |
| SI2401384T1 (sl) | 2013-01-31 |
| CN102597246A (zh) | 2012-07-18 |
| ES2394797T3 (es) | 2013-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121048T1 (hr) | Reverzna genetika korištenjem ne-endogenih pol i promotora | |
| HRP20201185T1 (hr) | Gdf zamke | |
| MY161891A (en) | Virus like particle production in plants | |
| NZ590144A (en) | Influenza virus-like particles (vlps) comprising hemagglutinin | |
| JP2011182797A5 (hr) | ||
| JP2015119730A5 (hr) | ||
| MX2011009105A (es) | Fraccionamiento de biomasa de algas. | |
| WO2010089151A8 (en) | Bioreactor for the cultivation of mammalian cells | |
| NO20062683L (no) | P EF-TU- ekspresjonsenheter | |
| WO2013049121A3 (en) | Recombinant phage and methods | |
| MX2014002497A (es) | Sintasa isopropilmalato de nicotiana tabacum y metodo y usos de la misma. | |
| MY172266A (en) | Threonine synthase from nicotiana tabacum and methods and uses thereof | |
| MX2013011601A (es) | Promotor especifico de semilla en alogodon. | |
| NZ700181A (en) | Plant cytochrome p450 | |
| NZ622731A (en) | Increasing virus-like particle yield in plants | |
| RU2015151124A (ru) | Способ получения l-аминокислот | |
| JP2010531148A5 (hr) | ||
| MX2015001543A (es) | Uso de una xilanasa en maíz y sub-productos de maíz. | |
| WO2012169819A3 (ko) | 2-하이드록시부티레이트를 모노머로 함유하고 있는 폴리하이드록시알카노에이트의 제조방법 | |
| WO2013030176A3 (en) | Live attenuated influenza virus | |
| MY194223A (en) | Method and microorganism for methionine production by fermentation with improved methionine efflux | |
| CA2797888A1 (en) | A method of stabilizing mrna | |
| WO2016068656A3 (ko) | 사이코스 에퍼머화 효소의 발현 시스템 및 이를 이용한 사이코스의 생산 | |
| WO2014044626A3 (en) | Process for producing gelatin employing aspergillopepsin ii | |
| JP2016538000A5 (hr) |